anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Medical devices commonly used for the treatment and care of critically ill patients can cause pressure injuries in intensive care units (ICUs). The endotracheal tube (ETT) is one of the most common medical devices to cause pressure injuries.
AIM: This study investigated the incidence of, characteristics of and risk factors for ETT-related pressure injuries for ICU patients.
STUDY DESIGN: This study adopted a prospective descriptive research design. The sample consisted of 146 endotracheally intubated patients. Data were collected using a patient information form, an Endotracheal Tube-Related Pressure Injuries Assessment Form, the Braden Risk Assessment Tool and the Nutritional Assessment Test.
RESULTS: The study revealed that 80.14% of the patients developed ETT-related pressure injuries. Over half of the ETT-related pressure injuries appeared on Day 3 or 4 (56.41%). High body mass index was found to be associated with the development of ETT-related pressure injuries (OR: 1.15, 95% CI: 1.05-1.26, p = .003). None of the other variables were statistically significant in the development of pressure injuries.
CONCLUSIONS: The incidence of ETT-related pressure injuries was quite high in the internal, surgical and anaesthesia ICUs. High body mass index was associated with the development of ETT-related pressure injuries. Intensive care nurses should implement interventions to prevent ETT-related pressure injuries in critically ill patients receiving mechanical ventilation support.
RELEVANCE TO CLINICAL PRACTICE: ETT-related pressure injuries are common in ICU patients. High body mass index was associated with the development of ETT-related pressure injuries in critically ill patients. The skin and mucosa should be assessed for the development of ETT-related pressure injuries during the daily assessment of the patients receiving mechanical ventilation support. The ETT should be repositioned regularly, and the most suitable ETT fixation method should be used.
Patients undergo collection of blood during a regular care visit or not up to 4 times a year. Extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. During bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. Patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. Patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data.
CLARINEX (desloratadine) Tablets are light blue, round, film coated tablets containing 5 mg desloratadine, an antihistamine, to be administered orally. It also contains the following excipients: dibasic calcium phosphate dihydrate USP, microcrystalline cellulose NF, corn starch NF, talc USP, carnauba wax NF, white wax NF, coating material consisting of lactose monohydrate, hypromellose, titanium dioxide, polyethylene glycol, and FD&C Blue #2 Aluminum Lake.

CLARINEX Syrup is a clear orange colored liquid containing 0.5 mg/1 mL desloratadine. The syrup contains the following inactive ingredients: propylene glycol USP, sorbitol solution USP, citric acid (anhydrous) USP, sodium citrate dihydrate USP, sodium benzoate NF, disodium edetate USP, purified water USP. It also contains granulated sugar, natural and artificial flavor for bubble gum and FDC Yellow #6 dye.

The CLARINEX RediTabs® brand of desloratadine orally-disintegrating tablets are light red, flat-faced, round, speckled tablets with an "A" debossed on one side for the 5 mg tablets and a "K" debossed on one side for the 2.5 mg tablets. Each RediTabs Tablet contains either 5 mg or 2.5 mg of desloratadine. It also contains the following inactive ingredients: mannitol USP, microcrystalline cellulose NF, pregelatinized starch, NF, sodium starch glycolate, NF, magnesium stearate NF, butylated methacrylate copolymer, crospovidone, NF, aspartame NF, citric acid USP, sodium bicarbonate USP, colloidal silicon dioxide, NF, ferric oxide red NF and tutti frutti flavoring.

Desloratadine is a white to off-white powder that is slightly soluble in water, but very soluble in ethanol and propylene glycol. It has an empirical formula: C19H19ClN2 and a molecular weight of 310.8. The chemical name is 8-chloro-6,11-dihydro-11-(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine and has the following structure:
PROBLEM TO BE SOLVED: To obtain the subject side effect-reducing agent for reducing side effects such as medicine-induced gastrointestinal dysfunction, etc., of nonsteroidal antiphlogistic sedative agent such as indomethacin or aspirin, containing sulfated polysaccharide as an active ingredient. SOLUTION: This side effect-reducing agent comprises sulfated polysaccharide (preferably fucoidan) as an active ingredient. The fucoidan is preferably obtained by subjecting alga to extraction with hot water in an acidic area, neutralizing the extract and removing residue after extraction. Fucoidan has good effect on nonsteroidal antiphlogistic sedative agent by administration of 0.08-8.0 mg/kg/ time. An antiphlogistic sedative agent scarcely having side effects is obtained by preparing the side effect-reducing agent and a nonsteroidal antiphlogistic sedative component. The form can be prepared as a liquid preparation such as syrup or emulsion or a solid preparation such as tablet. A vehicle, a binder, lubricant, etc., can be used for preparation of the solid preparation and a solvent, a solubilizer, etc., can be used for preparation of the liquid preparation.
TARGIT is an international randomised clinical trial designed to test the hypothesis that the strategy of delivering a single dose of targeted intraoperative radiotherapy (IORT) in patients eligible for breast conserving therapy (with the addition of whole breast radiotherapy in those patients at high risk of recurrence elsewhere in the breast \[e.g. lobular carcinomas and extensive intraductal component\]) is equivalent to a conventional course of post-operative external beam radiotherapy (EBRT). The primary endpoints are local and loco-regional recurrence rates. It is a pragmatic trial in which each participating centre has the option to define more restrictive entry criteria than in the core protocol. Only centres with access to the Intrabeam® (Carl Zeiss) enter patients into the trial. Eligible patients are those with tumours of good prognosis suitable for breast conserving surgery. After giving consent patients are randomised to either IORT or to EBRT. They may receive any other adjuvant treatments as deemed necessary, except for neoadjuvant therapy. The protocol requires that patients be followed at six monthly intervals for five years and then annually.
A medical image modeling system and a medical image modeling method are provided. The medical image modeling system includes an input device, a processing device, and a storage device. The input device obtains medical image data. The processing device is coupled to the input device. The processing device converts the medical image data into a bone model in response to a first operational command. The storage device is coupled to the processing device. The storage device stores a model database. The processing device reads the model database in response to a second operational command to obtain a bone reconstruction block corresponding to a defect block of the bone model. The processing device integrates a bone reconstruction model depicted corresponding to the bone reconstruction block into the defect block of the bone model to generate an integrated bone model.
FIELD: medicine; medical engineering. SUBSTANCE: device has container enclosing internal cavity for storing inhalation anesthetic agent. It is manufactured from a material, containing compound selected from a group composed of polyethylene naphthalate, polymethyl pentene polypropylene, polyethylene, ionomeric raisins and their combinations. The device has some quantity of Sevoflurane disposed in the mentioned internal cavity restricted by the container. Method involves providing predetermined quantity of Sevoflurane and container enclosing the internal cavity and manufactured from a material containing a compound selected from a group composed of polyethylene naphthalate, polymethyl pentene polypropylene, polyethylene, ionomeric raisins and their combinations. The mentioned predetermined quantity of Sevoflurane is introduced into the mentioned internal cavity enclosed into the mentioned container. EFFECT: long term drug storage; long service life of container. 17 cl, 1 dwg
PROBLEM TO BE SOLVED: To obtain a composition having action promoting oxidative phosphorylation, especially in mitochondoria and smoothing production of ATP and useful for treatment and prevention for many diseases accompanied by physical fatigue and mental fatigue and promotion of recovery after occurrence of fatigue thereby. SOLUTION: This composition contains (A) midodrine hydrochloride and (B) biotin as active ingredients. Furthermore, effective daily dose of the component A is 50μg to 50000μg as a health adult and effective daily dose of the component B is 250μg to 10000μg as health adult. The blend amount of the component B is 0. 2-10 pts.wt. based on 1 pts.wt. component A. Further, a water- soluble vitamin such as pantothenic acid, thiamine or nicotine is preferably used as a adjuvant so as to ensure the effect.
SAP block will be applied to the patient's serratus anterior fascia using 20 ml of 0.25% bupivacaine solution. Then, PIFB will be applied to the patient's parasternal region using 10 ml of 0.25% bupivacaine solution.
Participants will be randomly assigned as per cross-over design to receive a single dose of 2 Advil PM Liqui-Gels Minis capsules orally on day 1 of period 1 and will receive single dose of 2 Advil PM Liqui-Gels capsules orally on day 1 of period 2 with at least 7 days washout period. Participants will be instructed to consume the entire amount of ambient temperature water (approximately 240 milliliters \[mL\]) along their investigational product.
Traditional biopsy requires the removal, fixation, and staining of tissues from the human body. Its procedure is invasive and painful. Non-invasive in vivo optical biopsy is thus required, which should provide non-invasive, highly penetrative, three-dimensional (3D) imaging with sub-micron spatial resolution. Optical biopsy based on scanning two-photon fluorescence microscopy (TPFM) is a good method for biopsy of skin due to its high lateral resolution, low out-of-focus damage, and intrinsic three-dimensional (3D) section capability. However current technology still presents several limitations including low penetration depth, in-focus cell damages, and multi-photon phototoxicity due to high optical intensity in the 800 nm wavelength region, and toxicity if exogenous fluorescence markers were required. We study the harmonics optical biopsy of a human skin sample using a femtosecond Cr:forsterite laser centered at 1230 nm. Higher harmonics generation is known to leave no energy deposition to the interacted matters due to their energy-conservation characteristic. This energy-conservation characteristic provides the "noninvasive" nature desirable for clinical imaging. In our study, we will evaluate the clinical applications of optical skin biopsy using harmonic generation microscopy.
OBJECTIVE: Pain often accompanies carpal tunnel syndrome and affects patients' health-related quality of life. The aim was to develop and validate a predictive model for the pain intensity of carpal tunnel syndrome using demographic, clinical, electrophysiological, and ultrasound findings.
METHODS: We conducted a secondary analysis of data from a large sample of patients (May 2017 to December 2022) with carpal tunnel syndrome. A total of 520 (53.0 %) mild, 276 (28.1 %) moderate, and 186 (18.9 %) severe syndromes were included in the complete data set of 982 hands (61.1 % female). The mean age was 57.8 (10.7) years and the median duration [interquartile range] of the symptoms was 4 [2,10] months. A regression model was developed and validated to predict pain intensity on a numerical rating scale using a tree-based machine learning algorithm.
RESULTS: The validation of the regression model showed good performance with a root mean squared error, R-squared, and mean absolute error of 1.35, 0.42, and 1.05, respectively. Overall, the top significant predictors of pain intensity were compound motor nerve action potential latency, nocturnal pain, and thenar weakness. These were followed by the cross-sectional area of the median nerve, sensory nerve action potential, bowing of the flexor retinaculum, disease duration, and body mass index. We did not find strong associations between the median nerve transcarpal latency, age, sex, and diabetes with the pain intensity of carpal tunnel syndrome.
CONCLUSION: Our model showed good performance in predicting the subjective pain intensity of carpal tunnel syndrome, even in the context of non-linear relations.
Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
Group IV will include cases classified as class II obese, with a body mass index of 35.0-39.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
<P>PROBLEM TO BE SOLVED: To provide a dental composition having viscosity excellent in coatability and applicability, giving no dripping from an objective coated part and no viscosity raising and no gelation during preservation in a freezer or for long term preservation and suitable for application as an etching material.  <P>SOLUTION: The dental composition contains an acid such as phosphoric acid or the like, water and a polyvinyl alcohol having ≤0.53 diad syndiotacticity and has 0.01-5.00 pH. In the composition, the content of the polyvinyl alcohol having ≤0.53 diad syndiotacticity is 0.2-10 pts.wt. based on 100 pts.wt. sum total of the acid and water.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Non-communicable diseases have become one of the causes of premature mortality among the able-bodied population. The risk factors these diseases are individual characteristics of the diet and nutritional regimen. Their timely detection and correction are necessary for the early diagnosis, treatment and prevention of chronic non-communicable diseases. The purpose of the study was to determine the features of the structure of the actual consumption of the main food groups and the eating behavior of outpatients who are subject to periodic medical examinations and consider themselves healthy. Material and methods. The observational stratified study has been conducted. Сlinical data, data on physical activity (International Questionnaire on Physical Activity) were collected, an analysis of actual food consumption was carried out (using the Nutri-Prof software package) detailing individual nutrition in 228 outpatients (122 men and 106 women aged 18 to 72 years). Results. The eating behavior of patients who consider themselves healthy was often characterized by a lack of regularity of meals and an imbalance in the composition of the diet. The need for its correction was determined in 183 (80.3%) patients. The majority of patients revealed the following motives for an unhealthy eating style: "there are no reasons preventing a healthy diet" and "I am quite healthy, I can afford not to follow the rules of a healthy diet", every fifth patient has "the lack of a supportive person in creating a proper diet". Among men, higher consumption of meat products, eggs, bakery, potatoes, added sugar and added salt was significantly more common (p<0.05); in the diet of women there was a significantly higher level of dairy products, vegetable oil and vegetables was significantly (p<0.01). With high physical activity, a tendency was found to consume foods in accordance with modern criteria of a healthy diet, and with low physical activity, patients did not comply with the norms of a healthy diet. They consumed less fish products, vegetables, fruits, vegetable oils (p<0.01) and eggs (p<0.05), more bakery (p<0.05) with more pronounced excess intake of added sugar (p>0.05) and salt (p<0.05). Conclusion. Dietary pattern of patients who consider themselves healthy, developed during their lifetime, requires its correction by an outpatient physician within the framework of therapeutic and preventive consultations.
Stroke is the leading cause of disability in the United States with approximately 795,000 new or recurrent strokes per year. An estimated two thirds of patients post-stroke cannot incorporate the affected upper extremity (UE) into their activities of daily living. In addition, stroke survivors experience a 60% decrease in cardiovascular capacity, which contributed to disability and diminished quality of life. Developing rehabilitation techniques to optimize motor recovery while improving cardiovascular endurance would benefit the stroke population.

Animal studies using a forced exercise (FE) paradigm, in which the rodent is exercised on a motorized treadmill at a rate greater than its voluntary rate, indicate an endogenous increase in neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF). These neurotrophic factors are thought to underlie neuroplasticity and motor learning. It is hypothesized that patients with stroke, due to decreased motor cortical output, cannot sustain high rates of voluntary exercise necessary to trigger the endogenous release of neurotrophic factors; therefore, forced-exercise is necessary to augment their voluntary efforts and will be superior to voluntary exercise in facilitating motor recovery. When coupled with repetitive task practice (RTP) of the UE, an effective form of UE rehabilitation, FE will prime the brain for neuroplasticity. We have developed a safe and effective method of delivering forced-exercise to Parkinson's disease (PD) patients (NIH R21HD056316). Clinical and imaging data with PD patients indicate forced-exercise, but not voluntary exercise, triggers a neurophysiologic response in the central nervous system resulting in global improvements in motor and non-motor functioning and increased cortical and subcortical activation. The aim of this project is to conduct a preliminary trial to compare the effects of forced to voluntary exercise when coupled with RTP in promoting the recovery of motor function in patients with stroke.
PURPOSE: Provided are compounds and methods for modulating chloride ion transport, and, more specifically, antagonists and agonists of inositol polyphosphates. CONSTITUTION: Provided are compositions which are cell permeable antagonists of inositol polyphosphates. For example, antagonists of myo-inositol 3,4,5,6-tetrakisphosphate and phosphatidylinositol trisphosphate are provided. In addition, methods are provided which enhance chloride ion secretion from a cell by contacting the cells with cell permeable antagonists of inositol polyphosphates. Also provided are methods for enhancing chloride ion secretion in an individual by administering cell permeable antagonists of inositol polyphosphates to the individual. Additionally provided are methods for alleviating a sign or symptom associated with cystic fibrosis in an individual by administering a cell permeable antagonist of inositol polyphosphates to the individual. Compositions are provided which are cell permeable agonists of inositol polyphosphates. For example, provided are agonists of myo-inositol 3,4,5,6-tetrakisphosphate and phosphatidylinositol trisphosphate. In addition methods are provided which decreases chloride ion secretion from a cell by contacting the cell with cell permeable agonists of inositol polyphosphates. Also provided are methods for decreasing chloride ion secretion in an individual by administering cell permeable agonists of inositol polyphosphates to the individual. Additionally provided are methods for alleviating a sign or symptom associated with secretory diarrhea in an individual by administering cell permeable agonists of inositol polyphosphates to the individual.
Dyspnea and pain share many features. One of them is the counterirritation phenomenon: defined in pain research as the attenuation of one pain by another pain. Dyspnea induced with inspiratory threshold loading (increased sense of work/effort ) has been shown to attenuate electrical pain as shown through nociceptive flexion reflex inhibition, or thermal pain, as measured with cortical evoked responses (laser evoked potentials-LEP).

The investigators will study whether nefopam modulates the counterirritation of laboratory induced dyspnea in healthy subjects. The effect of nefopam on experimental dyspnea will be measured with a visual analog scale (VAS) and a validated multidimensional dyspnea profile (MDP). The effect of treatment on counterirritation will be measured by recording LEP obtained using a CO2 laser system. The amplitude of the N2-P2 component of the LEP is the main study outcome.
Management of type 2 diabetes mellitus (T2DM) using dipeptidyl peptidase IV (DPP IV) inhibitors is gaining precedence as this enzyme plays an indispensable role in cleaving and inactivating peptides, such as glucagon-like peptide-1 (GLP-1), incretin hormones, and glucose-dependent insulinotropic polypeptide (GIP). There are several DPP IV inhibitors used to treat T2DM, but limited by side effects such as disturbed GIT, flu-like symptoms, etc. Thus, there is an urgent need for the development of novel and better DPP IV inhibitors for the management of the same. In the present study, we investigated the effect of new boronic acid-based thiazole compounds as DPP IV inhibitors. We used substituted anilines that were progressively modified through a multi-step synthesis and then chemically characterised. These molecules have good binding affinity and molecular interactions at the active site of the DPP IV enzyme. Two boronic acid-based molecules, i.e. PC06R58 and PC06R108, were used for the assessment of their in-vitro enzymatic activities. Both molecules (PC06108 and PC06R58) exhibited potent uncompetitive DPP IV enzyme inhibition at two different concentrations of 90.9 and 15.6 nM, respectively, compared to sitagliptin having an IC50 of 17.3 nM. Furthermore, the oral glucose tolerance test suggested significantly reduced blood glucose levels at 20 mg/kg of the body weight upon administration of PC06R58 and PC06R108 molecules in rats after glucose ingestion (2 g/kg of the body weight). The compounds showed satisfactory DPP IV inhibition. Furthermore, DPP IV inhibitory activity and acceptable pre-ADME/Tox profile indicate it is a lead compound in this novel class of DPP IV inhibitors.Communicated by Ramaswamy H. Sarma.
All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.